Borrelia Infections
Conditions
Keywords
Borreliosis, Lyme, Borrelia Infections, Borrelia Burgdorferi, Borrelia Miyamotoi, Anti-CD20 monoclonal antibodies
Brief summary
Clinical, biological, radiological, and pharmacological description of cases of disseminated borreliosis (Borrelia burgdorferi sl. and Borrelia miyamotoi) occurring in patients who received drug treatment based on anti-CD20 monoclonal antibodies.
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Minor or adult subject * Having presented disseminated borreliosis confirmed by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.
Exclusion criteria
\- Refusal to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of the clinical presentation of cases of disseminated borreliosis occurring in patients receiving anti-CD20 therapy in France | Up to 12 months | The clinical presentation describes how the disease manifests in patients: * the symptoms, * their severity, * and their progression. Example: Two patients may have the same disease, but one will primarily experience fever while the other will have neurological symptoms. This is part of the clinical presentation. |
Countries
France
Contacts
Primary ContactPierre BOYER, MD
Outcome results
None listed